At what enterprise value was FEED ENZYME ALLIANCE acquired in 2025?

You can find the full valuation details of FEED ENZYME ALLIANCE on mynth capital. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of FEED ENZYME ALLIANCE when it was acquired by NOVONESIS?

The estimated EV/EBITDA multiple for FEED ENZYME ALLIANCE is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was FEED ENZYME ALLIANCE acquired by NOVONESIS?

FEED ENZYME ALLIANCE was acquired by NOVONESIS in 2025.

What was the EBITDA of FEED ENZYME ALLIANCE during the acquisition?

FEED ENZYME ALLIANCE's EBITDA is estimated to be in the range of 50M - 100M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the FEED ENZYME ALLIANCE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the FEED ENZYME ALLIANCE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.novonesis.com/en/news/novonesis-acquire-dsm-firmenichs-share-feed-enzyme-alliance

← DATABASE

Home Database Healthcare & PharmaFEED ENZYME ALLIANCE

02/2025

FEED ENZYME ALLIANCE acquired by NOVONESIS

DENMARK Life Sciences / Animal Health EV 1b - 4b EUR

Context

This transaction is a strategic corporate carve-out and vertical integration wherein Novonesis fully acquires the sales and distribution activities of the Feed Enzyme Alliance from its long-term joint venture partner, dsm-firmenich. Supported by a fully committed debt financing package, this operation effectively dissolves the historical alliance, granting Novonesis absolute control over the entire commercial value chain. The primary strategic rationale underpinning this acquisition is to directly combine the acquirer's established innovation and production capabilities with the target's extensive global go-to-market network. This powerful consolidation will significantly accelerate Novonesis's market penetration, unlock substantial revenue synergies, and solidify its undisputed leadership position within the global animal nutrition and biosolutions industry.

FEED ENZYME ALLIANCE, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

The Feed Enzyme Alliance was a 25-year joint venture focused on the development, production, and distribution of enzymes for animal nutrition. By delivering highly innovative, sustainable nutritional solutions and market-leading feed enzymes, the enterprise serves a broad, diverse customer base across the global animal nutrition and health sectors. Its robust commercial operations provide deep insights into core markets, fostering continuous technological innovation and sustainable value creation within the agricultural supply chain.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2025

2024

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
03/2025	NUTRISENS	PRODIET	BRAZIL	Life Sciences	Nutrisens Group has acquired a majority stake in Prodiet Medical Nutrition, a Brazilian leader in clinical nutrition. The founders of Prodiet, Armando Tortelli and Ana Paula Celes, retain a minority stake and will continue to support the company's growth, while Gabriel Tortelli remains as CEO
03/2025	SIPAREX	LABORATOIRE POLIDIS	FRANCE	Life Sciences	Laboratoire Polidis has completed its first-ever capital opening. Siparex Entrepreneurs and UI Investissement have joined the company as minority shareholders to support its next growth phase and formalize a new managerial transition
02/2025	EURAZEO / TURENNE CAPITAL / KURMA PARTNERS	GERMITEC	FRANCE	Life Sciences	Germitec raised EUR29 million in a Series B round led by Eurazeo to accelerate its commercial expansion in the United States. The company recently achieved a major regulatory milestone by obtaining FDA "De Novo" clearance in September 2024
01/2025	QUADRIVIO GROUP	MIR - MEDICAL INTERNATIONAL RESEARCH	ITALY	Life Sciences	The secondary buyout of 100% of Medical International Research by Quadrivio Group triggers the complete exit of the incumbent private equity sponsor Aksìa SGR. This ownership transition follows an operational phase marked by an annualized revenue expansion and the successful launch of subscription-based software services
12/2024	NEXTSTAGE / IK PARTNERS	EUROBIO SCIENTIFIC	FRANCE	Life Sciences	EB Development (Consortium: NextStage AM & IK Partners) has successfully concluded its takeover bid for Eurobio Scientific, following the results of a reopened offer period. The consortium now holds 88
12/2024	UI INVESTISSEMENT	DIDACTIC	FRANCE	Life Sciences	Didactic reorganized its shareholder base to accelerate its transformation into a European industrial leader. GENEO Capital Entrepreneur and UI Investissement acquired a majority stake, taking over from the previous sponsor
11/2024	NAXICAP PARTNERS	GLOBAL D	FRANCE	Life Sciences	Naxicap Partners has acquired a majority stake (over 60%) in Global D, marking the company’s first independent LBO following its carve-out from the Menix Group. The remaining capital is held by a dozen managers led by the executive team
10/2024	KKR / KREFELD	ANJAC BEAUTY & HEALTH	FRANCE	Life Sciences	Anjac reorganized its capital by welcoming KKR and Krefeld as minority shareholders, following a competitive process led by Rothschild & Co. The EUR450M investment allowed the exit of historical partners Andera Partners, Bpifrance, and IDIA
10/2024	BANSK GROUP	PETIQ	UNITED STATES	Life Sciences	Bansk Group completed the acquisition of 100% of PetIQ in an all-cash public-to-private transaction. PetIQ was delisted from Nasdaq upon closing and is now operated as a privately held company, with founder Cord Christensen continuing as CEO
10/2024	CLAYTON, DUBILIER & RICE (CD&R)	OPELLA	FRANCE	Life Sciences	Sanofi has announced the sale of 50% of its stake in Opella to the American fund CD&R. Opella Healthcare (formerly Sanofi Consumer Healthcare) is a company specializing in consumer healthcare products

REFERENCES

Valuation range: EV 1b - 4b EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of FEED ENZYME ALLIANCE by NOVONESIS are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Acquirer: novonesis